* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 9-Methyl-7-Bromoeudistomin D, a Caffeine Like
Pharmacogenomics wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
DNA-encoded chemical library wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Discovery and development of tubulin inhibitors wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Neuropharmacology wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Toxicodynamics wikipedia , lookup
Discovery and development of integrase inhibitors wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
9-Methyl-7-Bromoeudistomin D, a Caffeine Like Ca2+ Releaser, Probably Binds to Cytochromes P-450 1A1 and 2B in Liver Microsomes Masae Kakubari1),Masatoshi Adachi1),Masakuni Degawa2) ,Yasushi Ohizumi1,2,3,4) 1)Department of Pharmaceutical Moleculer Biology, Pharmacetical Insutitute, Tohoku University, Aoba, Aoba-ku,Sendai 980-8578,Japan 2)Department of Molecular Toxicology, School of Pharmaceutical Sciences,23 University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan 3)Department of Anti-dementia Functional Food Development, Research Center of 75 Supercritical Fluid Technology, Graduate School of Engineering, Tohoku University,76 6-6-07 Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan 4)Laboratory of Kampo Medicines, Yokohama College of 65 Pharmacy, 601 Matano-cho, 66 Totsuka-ku, Yokohama 245-0066, Japan Received October 3, 2011, Accepted December 7,2011 3 H-labeled 9-metyhl-7-bromoeudistomin D (3H-MBED), a powerful caffeine-like Ca releaser binds to liver microsomes as well as the caffeine binding site of terminal cisternae of skeletal muscle sarcoplasmic reticulum(SR)(Fang at al.,1993; Adachi et al.,1994). 3H-MBED binding to rabbit liver microsomes was inhibited by alpha-naphthoflavone (α-NF), a cytochrome P450 (CYP) 1A1/1A2 inhibitor in a concentration-dependent manner (IC ≒ 3 nM), while that was not affected by alpha-phenyl- alpha-prorylbenzeneacetic acid N,N-diethylaminoethy1-2,2-diphenylvalerate hydrochloride (SKF525A), an inhibitor for several CYPs including CYP2B subfamily enzymes. We comparatively examined the binding levels of 3H-MBED to liver microsomes from rats treated by β-NF, phenobarbital (PB), and 2-methoxy-4-aminoazobenzene (2-MeO-AAB). The enhanced binding levels were observed in the microsomes from rats treated with by β-NF (CYP1A1/1A2 inducer) and PB (CYP2B inducer), but not 2-MeO-AAB (CYP1A2-selevtive inducer). The 3H-MBED binding levels to the microsomes from β-NF-treated rats were inhibited by α-NF but not by SKF525A, whereas the activities to those from PB-treated rats were decreased by SKF525A but not by α-NF. Furthermore, the enhanced binding levels of 3H-MBED were inhibited by addition of caffeine. The present findings suggest that 3H-MBED binds to CYP1A1 and CYP2B in liver microsomes. Keywords: 9-Methyl-7-bromoeudistomin D / ca releaser / cytochromes P-450 / binding sites Introduction It has been shown that 9-methyl-7-bromoeudistomin D (MBED), a derivative of eudistomin, D isolated from Cribbean tunicate Eudistoma olivaceum, is a powerful Ca2+ releaser from ryanodine receptor with properties similar to caffeine (Nakamura et al.,1986; Kobayahshi at al.,1986; Seino et al., 1989) and that 3H-labeled MBED binds to the caffeine binding site of skeletal and smooth muscle sarcoplasmic reticulum (SR) (Fang et al.,1993; Adachi et al., 1994). 3H-MBED bound to rabbit liver microsomes with a more than (30)-fold greater receptor density compared with that of SR (Adachi et al., 1994). Furthermore, caffeine non-competitively inhibited *Correspondence author: Dr.Yasushi Ohizumi, . Graduate School of Engineering, Tohoku University, 6-6-07 Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan Tel: +81-22-795-7248 Fax: +81-22-795-7246 E-mail: [email protected] 3 H-MBED binding to liver microsomes, these results suggesting that the property of the 3H-MBED binding site in liver microsomes is distinct from that in skeletal SR (Adachi et al., 1994; Adachi et al., 1994). In this paper, to clarify the 3H-MBED binding site in the liver microsomes, we comparatively examined the 3 H-MBED binding activities to the liver microsomes from rats treated with different types of cytochorome P450 (CYP) inducers. Fig.1. Chemical structure of tritium labeled 9-methyI-7-bromoeudistomin D (3H-MBED) Materials and Methods 1. Chemicals 3 H-labeled MBED (fig.1) was synthesized as previously described (Fang et al., 1993) with as specific radioactivity of 10.2 ci/mmol. 3H-MBED was dissolved in DMSO of which the final concentration was kept at< 2% (v/v) in all the experiments. 2-MeO-AAB was synthesized as previously described (1987). Aprotinin, benzamidine hydrochloride, leupetine, pepstatin A and N,N-diethylaminoethy1-2,2-diphenylvalerate hydrochloride (SKF525A) were obtained from Wako Pure Chemical Industries (Tokyo,Japan). α-NF, PB and 30% polyethleneimine were obtained from Tokyo Chemical Industries (Tokyo,Japan). 2. Induction of CYP and preparation of liver microsomes. Seven-week-old male F334 rats were used. The following drugs were used to induce CYP: PB (0.11 mmol/kg, i.p.,in corn oil), 2-MeO-AAB (0.22 mmol/kg, i.p., in corn oil and β-NF 0.22 mmol/kg, i.p., in H2O). The liver was excised 24hr after the administration of the inducers and rat liver microsomes were prepared as described (Degawa et al., 1986). Rabbit liver microsomes were prepared from male Japanese White rabbits weighing about 3kg as previously described (Adachi et al., 1994). Protein concentrations were measured by the method of Bradford (Bradford, 1976) using a protein assay kit (Bio-Rad) with BSA as standard. 3. 3H-MBED binding assay Fig.2. Effects of CYP inhibitors on 3H-MBED binding to rabbit liver microsomes Rabbit liver microsomes (25 μg protein) were incubated with 50 nM 3H-MBED in the absence or presence of various concentrations of α-NF and SKF525A for 45 min at 0 ℃ as described in “ Material and Methods”. The symbols indicate the means, and the bars represent their standard errors (n=3). Fig.3. Comparison of the binding level of 3H-MBED to the liver microsomes from the rats treated with different CYP inducers 2-MeO-AAB-, β-NF- and PB-treated, or untreated rat liver microsomes (25μg) were incubated with 50 nM 3H-MBED for 45 min at 0 ℃ as described in “ Material and Methods”. 3 H-MBED binding assay was performed as described by Adachi et al (Adachi et al., 1994). Liver microsomes (25μg protein) were incubated with 3H-MBED (50nM) at 0℃ for 45 min in a solution containing 0.3 M surcrose, 2 mM DDT, 0.1 mM p-APMSF and 20 mM Tris-HCl (pH 7.4) in the presence or absence of drugs. The amount of 3 H-MBED bound was determined by filtration through polyethyleneimine-treated (3% for 45 min) Whatman filters (GF/B). The filters were washed twice with 5 ml of ice-cold 50mM Tris-HCl (pH 7.4). Specific binding levels were estimated by subtracting nonspecific binding level in the presence of 5 μM unlabeled MBED from total binding level. Results and Discussion α-NF, a CYP1A1/1A2-selective inhibitor (Murray and Reidy., 1990; Jenner and Netter., 1972), led to a concentration-dependent inhibition of 3H-MBED binding to rabbit liver microsomes with the IC50 value of 3nM, while SKF525A, an inhibitor for several CYPs including Fig.4. Effects of CYP inhibitors on 3H-MBED binding to the liver microsomes of β-NF-treated rats The liver microsomes (25 μg protein) from β-NF-treated rats were incubated with 50 nM 3H-MBED in the absence or presence of various concentrations of α-NF and SKF25 for 45 min at 0 ℃ as described in “ Material and Methods ”. The symbols indicate the means (n=3), and the bars represent their standard errors. Fig.5. Effects of CYP inhibitors on 3H-MBED binding to the liver microsomes of PB-treated rats The liver microsomes (25 μg protein) from PB-treated rats were incubated with 50 nM 3H-MBED in the absence or presence of various concentrations of α-NF and SKF25 for 45 min at 0 ℃ as described in “ Material and Methods ”. The symbols indicate the means (n=3), and the bars represent their standard errors. CYP2B subfamily enzymes (Enomoto, et al. 2005; Murray and Reidy.,1990; Jenner and Netter.,1972), has no effect as shown in fig.2. These results suggest that 3H-MBED binding site is related to CYP1A1/1A2 in rabbit liver microsomes. 2-MeO-AAB, β-NF and PB have been reported to be typical inducers of microsomal CYP1A2, CYP1A1/1A2 and CYP2B, respectively, in the rat liver (Hishinuma et al., 1987; Murray and Reidy.,1990). We examined the effect of treatment of rats with 2-MeO-AAB, β-NF, and PB on the binding levels of 3 H-MBED to the liver microsomes. The 3H-MBED binding levels were increased to 60 pmol/mg protein and 120 pmol/mg in β-NF- and PB-treated rats, respectively, whereas no such increase occurred in 2-MeO-AAB-treated rats (fig.3). Such enhanced 3H-MBED binding was markedly inhibited by addition of caffeine (3 mM). Furthermore, 3H-MBED binding to liver microsomes from β-NF-treated rats was concentration-dependently inhibited by α-NF (IC≒10 nM), but not by SKF525A (fig.4). In contrast, SKF525A caused an inhibition of 3 H-MBED binding to liver microsomes from rats treated with PB, a typical inducer of CYP2B subfamily enzymes, but α-NF, a typical inhibitor of CYP1A subfamily enzymes, had no effect on this binding (fig.5). These results suggest that in rat liver microsomes, 3H-MBED probably binds to CYP1A1 and CYP2B. We have previously reported that caffeine can allosterically inhibit 3H-MBED binding to rabbit liver microsomes and that the 3H-MBED binding site is distinct from but related to that of caffeine (Adachi et al., 1994). Although caffeine has been reported to be a good substrate for CYP1A2 (Arnaud, 1987; Butler, 1989; Wang and Zhou, 2009), binding level of 3H-MBED to liver microsomes from rats treated with 2-MeO-AAB, a CYP1A2-selective inducer, was not increased. This suggests that 3H-MBED does not necessarily bind at the substrate-binding site of CYP enzymes. References Adachi, M., Fang, Y.-L., Yamakuni, T., Kobayashi, J. and Ohizumi, Y. (1994) Properties of the binding site of [3H]9-methyI-7-bromoeudistomin D in bovine aortic smooth muscle microsomes, J. Pharm. Pharmacol., 46, 771-773. Adachi,M., Kakubari, M. and Oizumi, Y. (1994) Tissue and subcellular-distribution of the binding site of [3H]9-methyI-7-bromoeudistomin D, a potent caffeine-like Ca2+ releaser, in rabbit, J. Pharm. Pharmacol., 46, 774-776. Adachi,M., Kakubari, M. and Oizumi, Y. (1994) The specific binding site of 9-[3H] methyI-7-bromoeudistomin D, a caffeine-like Ca2+ releaser, in liver microsomes is distinct from that in skeletal salcoplasmic reticulm, Biolchem. Hopper-seyler., 375, 183-187. Arnaud, M.-J. (1987) The pharmacology of caffeine,Prog. Drug. Res., 31, 273-313. Bradford, M.-M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72, 248-254. Butler, M.-A.,Iwasaki,M., Guengerich, F.-P. And Kadlubar, F.-F. (1989) Human cytochrome P-450PA, the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxdation of carcinogenic arylamines, Proc. Natl. Acad. Sci. USA., 86, 7696-7700. Degawa,M., Kojima, M., Sato, Y. and Hashimoto, Y. (1986) Induction of a high spin form of microsomal cytochrome P-448 in rat liver by 4-aminoazobenzene derivatives, Biochem. Pharmacol., 35, 3365-3570. Degawa,M., Yamda, H., Hishinuma, T., Masuko, T. and Hashimoto, Y. (1987) Organ selective induction of cytochrome P-448 isoenzymes in rats by 2-methoxy-4-aminoazobenzene and 3-methylcholanthrene,J. Biochem., 101, 1437-1445. Enomoto, C., Murase, S., Sawada, Y. and Iwasaki, K. (2005) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A, Drug Metab. Pharmacokinet. 20, 351-357. Fang, Y.-L., Adachi, M., Kobayashi, J. and Oizumi, Y. (1993) High affinity binding of 9-[3H] methyI-7-bromoeudistomin D, to the caffeine-binding site of skeletal muscle sarcoplasmic reticulm, J. Biol. Chem., 268, 18622-18625. Hishinuma, T., Degawa, M., Masuko, T. and Hashimoto, Y. (1987) Induction of cytochrome p-448 isozyme(s) in primary cultured rat hepatocytes by drugs which induce defferent isozymes in vivo, Biochem. Biophys. Res. Commun., 148, 947-953. Jaw, S., Leffery, E.-H. (1993) Interaction of caffeine with acetaminophen hepatotoxicity and acetoaminophen bioactivation following treatment of mice with various cytochrome p 450 inducing agents, Biochem. Pharmacol., 46, 493-501. Jenner, S., Netter, K.-J. (1972) On The inhibition of microsomal drug metabolism by SKF-525A, Biochem. Pharmacol., 21, 1921-1927. Kobayahshi, J., Ishibashi, M., Nagai, U. and Ohizumi, Y. (1989) 9-methyI-7-bromoeudistomin D, a potent inducer of calcium release from sarcoplasmic reticulm of skeletal muscle, Experimentia, 45, 782-783. Murray, M., Reidy, G. (1990) Selectivity in the inhibition of mammalian cytochromes P-450, Chemical agents. Pharmacol.Rev., 42, 85-101. Nakamura, Y., Kobayashi, J., Gilmore, J., Mascal, M., Rinehart, K.-L. Jr., Nakamura, H. and Ohizumi, Y. (1986) Bromo-eudistomin D, a nobel inducer of calcium release from fragmented salcoplasmic reticulm that causes contractions of skinned muscle fibers, J. Biol. Chem., 261, 4139-4142. Seino, A., Kobayashi, J., Fang. Y.-L., Ishibashi, M., Nakamura, H., Momose, K. and Ohizumi, Y. (1989) 9-methyI-7-bromoeudistomin D, a powerful radio-labelable Ca2+ having caffeine-like properties, acts on Ca2+ induced Ca2+ release channels of sarcoplasmic reticulum, J. Pharmacol. Exp.,Ther.,256, 861-867. Wang, B., Zhou, S.-F. (2009) Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development, Curr. Med. Chem., 16, 4066-4218.